Is There any Difference between Modern Valves and Self and Balloon Expandable Valves?

At present TAVR is a valid alternative to treat different risk groups of patients with severe aortic stenosis.  Among the different valves, there are two types, the self-expanding (SEV) and the balloon expandable (BEV) valves, that are the most implanted and the most researched by randomized studies across different risk groups. There are different generations<a href="https://solaci.org/en/2022/12/16/is-there-any-difference-between-modern-valves-and-self-and-balloon-expandable-valves/" title="Read more" >...</a>

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

Patients with INOCA in the ISCHEMIA Trial

There has been an increase in the diagnosis of patients with proven ischemia who did not present obstructive coronary lesions (defined as the absence of stenosis ≥50%), called ischemia with non-obstructive coronary arteries (INOCA). These patients are at a higher risk for major adverse cardiac events (MACE) compared with the rest of the population. The<a href="https://solaci.org/en/2022/10/18/patients-with-inoca-in-the-ischemia-trial/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

SURTAVI at 5 Years

Transcatheter aortic valve replacement (TAVR) by transfemoral access has shown great benefit for different risk groups, but its long-term durability is still uncertain. Available evidence comes from small analysis and a single randomized trial with 280 patients and an 8 year follow-up: the NOTION Trial, where TAVR showed less valvular degeneration than aortic valve replacement (AVR) surgery.<a href="https://solaci.org/en/2022/10/17/surtavi-at-5-years/" title="Read more" >...</a>

Concurso de Jóvenes Cardiólogos Intervencionistas Jornadas Colombia 2022

The Winners of Colombia Sessions 2022

On October 6, 7 and 8 2022 the 54th Colombian Sessions were held (together with the Colombian Congress of Hemodynamics); a world class scientific event with prestigious cardiologists from the across the continent.  In this framework, the traditional Contest for Young Interventionists took place, and young professionals from different countries presented challenging case studies that<a href="https://solaci.org/en/2022/10/13/the-winners-of-colombia-sessions-2022/" title="Read more" >...</a>

stent-liberador-drogas-sirolimus-everolimus

The New Sirolimus Eluting Balloons Are Also Effective

The technological development of drug eluting stents has allowed us to treat increasingly complex patients, with around 10% stenosis and using more, and longer stents.  This situation generates a great challenge: keep using stents or use paclitaxel coated balloons (PCB). At present, there are sirolimus drug coated balloons (SCB), but we do not have enough<a href="https://solaci.org/en/2022/10/11/the-new-sirolimus-eluting-balloons-are-also-effective/" title="Read more" >...</a>

TCT 2022 | FAME-3 Trial: post PCI FFR And IVUS in Patients with Three-Vessel Disease

We are well aware of the benefits of Fractional Flow Reserve (FFR) to assess coronary artery stenosis. FFR after PCI (post-PCI FFR) has been shown to have prognostic value; however, few studies have included patients with complex three-vessel disease. The impact of intravascular ultrasound (IVUS) or optical computer tomography (OCT) in this field has been<a href="https://solaci.org/en/2022/09/22/tct-2022-fame-3-trial-post-pci-ffr-and-ivus-in-patients-with-three-vessel-disease/" title="Read more" >...</a>

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

TAVR in Bicuspid Patients: Are Outcomes the Same in Men and Women?

Bicuspid aortic valve stenosis (BAV) has not yet been analyzed in large, randomized studies, and TAVR in this scenario has been assessed only by small fairly studies. However, the information available is quite promising.   TAVR in women generally presents more complications than in men, but severe bicuspid aortic valve stenosis receiving TAVR has not been<a href="https://solaci.org/en/2022/08/26/tavr-in-bicuspid-patients-are-outcomes-the-same-in-men-and-women/" title="Read more" >...</a>

Surgical Bioprosthesis Deterioration: Is the Valve-in-Valve Technique a Good Option?

The use of surgical bioprostheses has significantly increased, and while they last 15 years or more, in cases where they fail (usually due to stenosis), the decision-making process is challenging. Transcatheter aortic valve replacement (TAVR) is a good alternative for this situation, although information on the subject matter is still scarce. Currently, the only available<a href="https://solaci.org/en/2022/08/18/surgical-bioprosthesis-deterioration-is-the-valve-in-valve-technique-a-good-option/" title="Read more" >...</a>

Non-Cardiac Surgery After TAVR Is Safe

There are increasingly more patients who have undergone transcatheter aortic valve replacement (TAVR) and require a non-cardiac intervention, or patients with other diseases who need surgery and are diagnosed with aortic stenosis.  In addition, on many occasions, surgery must be performed as soon as possible (as in cases of cancer) or is an emergency procedure.<a href="https://solaci.org/en/2022/08/11/non-cardiac-surgery-after-tavr-is-safe/" title="Read more" >...</a>

The Best of the SOLACI-SOCIME 2022 Main Arena: Day 3

Lecture by Dr. Hector García García – LM-PCI: IVUS and FFR/IFR? Dr. Hector García delivered an excellent presentation on whether we should use intravascular ultrasound (IVUS) or fractional flow reserve (FFR)/instantaneous wave-free ratio (iFR) in the left main coronary artery (LMCA) to consider severe obstruction, since there is significant interobserver variability with angiography. Although the<a href="https://solaci.org/en/2022/08/11/the-best-of-the-solaci-socime-2022-main-arena-day-3/" title="Read more" >...</a>

coronary stenosis